---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-24-000140"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:12:40.758338+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arvinas/Pfizer report vepdegestrant+abemaciclib Phase 1b: 62.5% CBR, 26.7% ORR in post-CDK4/6 breast cancer

## Summary
- 62.5% clinical benefit rate (10/16) and 26.7% ORR (4/15) in ER+/HER2- advanced breast cancer patients all previously treated with CDK4/6 inhibitor.
- No significant drug-drug interaction between vepdegestrant (200mg QD) and abemaciclib (150mg BID); no grade 4/5 TEAEs.
- Recommended Phase 2 dose confirmed: vepdegestrant 200mg QD + abemaciclib 150mg BID; Phase 2 portion ongoing.
- Data cut-off Aug 30, 2024; presented Dec 12, 2024 at SABCS; 5 of 16 patients remain on treatment.

## SEC filing metadata
- accession: 0001655759-24-000140
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000140/0001655759-24-000140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000140/arvn-20241210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-24-000140
- JSON: https://secwatch.observer/filing/0001655759-24-000140.json
- Plain text: https://secwatch.observer/filing/0001655759-24-000140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.